1. 1 Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial. (13th November 2020) Authors: Ledermann, J; Colombo, N; Oza, A; Fujiwara, K; Birrer, MJ; Randall, L; Poddubskaya, E; Scambia, G; Shparyk, YV; Lim, MC; Lim, MC; Sohn, J; Yonemori, K; Stewart, RA; Zhang, X; Perkins Smith, J; Linn, C; Monk, BJ Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 92O Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817. (15th December 2019) Authors: Barlesi, F; Audigier-Valette, C; Felip, E; Ciuleanu, T-E; Jao, K; Rijavec, E; Urban, L; Aucoin, J-S; Zannori, C; Vermaelen, K; Frontera, O Arén; Ready, N; Curioni, A; Linardou, H; Poddubskaya, E; Fischer, J R; Pillai, R; Li, S; Acevedo, A; Paz-Ares, L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗